Back to search
FDAFDA · Food and drugs·Recall number D-0499-2021

Auryxia (ferric citrate) tablets 210 mg* 200 Tablets Rx Only NDC 59922-631-01 Manufactured for and distributed by: Keryx Biopharmaceuticals, Inc. 750 Lexington Avenue, 20th Floor New York, NY 10022 USA

Published June 2, 2021 · Recall initiated: March 15, 2021

Summary

FDA records drug Class II recall D-0499-2021, published June 2, 2021 and initiated March 15, 2021. Recalling firm: Cardinal Health Inc.; Status: Terminated; Reported quantity: 136 bottles; Lot: AN0142D. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

What to do

Voluntary: Firm initiated · Letter

Get an email if AURYXIA has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
AURYXIA
Manufacturer
Cardinal Health Inc.
Distributor
FL, GA, SC
Lot
AN0142D
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Auryxia (ferric citrate) tablets 210 mg* 200 Tablets Rx Only NDC 59922-631-01 Manufactured for and distributed by: Keryx Biopharmaceuticals, Inc. 750 Lexington Avenue, 20th Floor New York, NY 10022 USA recalled?

Yes. FDA published recall D-0499-2021 on June 2, 2021. Reported hazard: CGMP Deviations: Intermittent exposure to temperature excursion during storage.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: AURYXIA.